Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-na ve GBM Patients.

STATUS

Recruiting
participants needed

10
sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Send

Updated on 19 February 2024

See if I qualify

white blood cell count

ejection fraction

temozolomide

glioblastoma multiforme

blood cell count

glioma

Summary

A multi-center, open-label, single-arm, phase I/II clinical study is designed to test the safety and immunogenicity of an investigational Dendritic and Glioma Cells Fusion vaccine given with IL-12 for treatment-nave patients after resection of glioblastoma.

Description

This clinical trail includes two phases: basic treatment phase and immunotherapy phase. In basic treatment phase, patients will receive concomitant radiation and TMZ-chemotherapy. In immunotherapy phase, besides maintenance chemotherapy with TMZ, Fusion cells will be administered with IL-12 to enhance the immunity of patients.

Details

Condition	Neuroectodermal Tumor, neurectoderma, biological response modifier, Cancer, Glioma, Glioblastoma Multiforme, Glioblastoma Multiforme, Gliomatosis cerebri, Vaccines, Vaccines, Neoplasms, Nerve Tissue, Germ cell tumor, neurectoderma
Age	18years - 75years
Treatment	Temozolomide, Dendritic Cell/Tumor Fusion Vaccine, Interleukin-12
Clinical Study Identifier	NCT04388033
Sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Age 18 years; Male or Female
	Treatment-nave patients after Resection of Glioblastoma
	Histologically confirmed Glioblastoma
	KPS 60
	White blood cell count (WBC) 3.0 x 109/L; peripheral blood lymphocyte (PBL) 25%
	Echocardiographic assessment of left ventricular ejection fraction (LVEF) 40% within 1 month of enrollment
	Patients must be able to understand the investigational nature of the study and provide informed consent
Exclusion Criteria
	Those who are allergic constitution, or allergic to biological products, or have contraindications to CT and MRI1 contrast agents
	Those with severe autoimmune diseases or immunodeficiency diseases
	Those who are expected to take systemic corticosteroids within three months
	Those who needs long-term usage of immunosuppressive agents
	Those with infectious diseases, including syphilis, AIDS, hepatitis B, hepatitis C, etc
	Those who plan to receive any other anti-tumor treatment during the trial
	Combined with serious primary diseases of cardiovascular, liver and kidney, and liver function (ALT, AST, Y-GT) exceeding 1.5 times of the upper limit: BUN or Cr exceeding 1.5 times of the upper limit of normal value
	Patients with other malignant tumors
	Those with active infections, etc
	Suspected or confirmed a history of alcohol and drug abuse
	Psychiatric illness, intellectual and language disabilities that compromise the informed consent process, at the discretion of the investigator
	Women who are pregnant or nursing
	Women of childbearing age who refuse to contraception
	Active participation in another clinical treatment trials
	According to the judgment of the investigator, other conditions that the plan cannot be followed

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

white blood cell count

ejection fraction

temozolomide

glioblastoma multiforme

blood cell count

glioma

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-na ve GBM Patients.